A.D.A.M. is a developer of an on-demand personalized implant manufacturing infrastructure with a full scope of related services, provided remotely or on site.
With A.D.A.M., medical professionals will be able to complete all steps of the implant-printing process from 3D-modeling to receiving a sterilized personalized device, ready for implantation.
TECHNOLOGY-AS-A-SERVICE MODEL
By designing and building an on-demand tissue manufacturing solution, A.D.A.M. has been pioneering the technology as a service model to effectively address a complex problem. The business model will allow patients to have their tissue modelled – using the MRI/CAT scans stored on the digital platform – and, subsequently, 3D-printed and implanted in certified clinics.
STEP 2
IMPLANT PRODUCTION
The resulting 3D model of the patient-specific bone implant will be used for its subsequent production using A.D.A.M. proprietary 3D printers. Printing may take place at A.D.A.M. or directly on site, subject to the medical institution's preferences.
Overall production time will take up to 24 hours, which is substantially faster compared to the existing alternatives. At the same time, use of 3D-printing technology and A.D.A.M. material composites results in a lower cost of production than for titanium or PEEK-based implants.
STEP 3
IMPLANTATION
A.D.A.M. will help medical professionals through a developed set of Quality Management System procedures, which will ensure safety, efficacy and quality of the implant.
Medical professionals will receive a sterilized 3D-printed bone implant ready for use in surgery.
STEP 3
IMPLANTATION
A.D.A.M. will help medical professionals through a developed set of Quality Management System procedures, which will ensure safety, efficacy and quality of the implant.
Medical professionals will receive a sterilized 3D-printed bone implant ready for use in surgery.
MILESTONES
• Pre-clinical trials completed in accordance with ISO standards• Safety, biocompatibility and resorbability tested and confirmed• FDA Q-submission response confirmed 510(k) rule eligibility• No human trials required• 3 PCT patents published (materials & BJP printer)• 1 provisional patent for FDM printer• Mount Sinai Innovation Partners' Elementa Labs startup
MILESTONES
• Pre-clinical trials completed in accordance with ISO standards• Safety, biocompatibility and resorbability tested and confirmed• FDA Q-submission response confirmed 510(k) rule eligibility• No human trials required• 3 PCT patents published (materials & BJP printer)• 1 provisional patent for FDM printer• Mount Sinai Innovation Partners' Elementa Labs startup